Unsupervised machine learning for multi-system adverse event pattern detection in pharmacovigilance: A proof-of-concept analysis of fluoroquinolone reports in FAERS.

IF 3 3区 医学 Q2 PHARMACOLOGY & PHARMACY
Niaz Chalabianloo, Sheikh S Abdullah, Kamran Sedig, Flory T Muanda
{"title":"Unsupervised machine learning for multi-system adverse event pattern detection in pharmacovigilance: A proof-of-concept analysis of fluoroquinolone reports in FAERS.","authors":"Niaz Chalabianloo, Sheikh S Abdullah, Kamran Sedig, Flory T Muanda","doi":"10.1002/bcp.70853","DOIUrl":null,"url":null,"abstract":"<p><strong>Aims: </strong>Traditional pharmacovigilance detects single drug-event associations but cannot readily characterize multi-system adverse-event patterns such as fluoroquinolone-associated disability. We evaluated unsupervised machine learning for this purpose, using fluoroquinolones as an exemplar.</p><p><strong>Methods: </strong>We analysed 40 127 adult fluoroquinolone primary-suspect reports from the FDA Adverse Event Reporting System (FAERS, 2004-2025). Events were encoded as binary MedDRA Preferred Term (PT) and System Organ Class matrices; seriousness and outcome were excluded from clustering and used only post hoc. Multiple correspondence analysis with k-means was primary, validated by k-modes and hierarchical clustering. Cluster number (k = 2-15) was assessed by internal validity indices with bootstrap stability. Comparators were macrolides (n = 39 948) and amoxicillin (n = 16 310).</p><p><strong>Results: </strong>At PT level, silhouette and Calinski-Harabasz indices were optimal at two clusters (Davies-Bouldin at three; silhouette 0.560), separating a multi-system cluster (4072 reports; 10.1%) enriched for neuropsychiatric, musculoskeletal and sensory terms (lifts: memory impairment 8.6, muscle atrophy 8.3, dry eye 7.8). Excluding seriousness and outcome left the cluster essentially unchanged (91.4% retained; κ 0.95), indicating definition by event topology, not case severity; independent algorithms recovered the same subgroup across granularities. Post hoc, the cluster was disproportionately disabling (43.0% vs. 11.7%). The fixed signature classified 14.9% of fluoroquinolone reports vs. 5.3% (macrolides) and 3.9% (amoxicillin).</p><p><strong>Conclusions: </strong>Unsupervised clustering of FAERS data identified, without prior clinical input, a reproducible multi-system adverse-event pattern among fluoroquinolone reports, potentially supporting the feasibility of unsupervised exploratory pattern detection in pharmacovigilance. Given the limitations of spontaneous reporting databases, the findings are strictly hypothesis-generating.</p>","PeriodicalId":9251,"journal":{"name":"British journal of clinical pharmacology","volume":" ","pages":""},"PeriodicalIF":3.0000,"publicationDate":"2026-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"British journal of clinical pharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/bcp.70853","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Aims: Traditional pharmacovigilance detects single drug-event associations but cannot readily characterize multi-system adverse-event patterns such as fluoroquinolone-associated disability. We evaluated unsupervised machine learning for this purpose, using fluoroquinolones as an exemplar.

Methods: We analysed 40 127 adult fluoroquinolone primary-suspect reports from the FDA Adverse Event Reporting System (FAERS, 2004-2025). Events were encoded as binary MedDRA Preferred Term (PT) and System Organ Class matrices; seriousness and outcome were excluded from clustering and used only post hoc. Multiple correspondence analysis with k-means was primary, validated by k-modes and hierarchical clustering. Cluster number (k = 2-15) was assessed by internal validity indices with bootstrap stability. Comparators were macrolides (n = 39 948) and amoxicillin (n = 16 310).

Results: At PT level, silhouette and Calinski-Harabasz indices were optimal at two clusters (Davies-Bouldin at three; silhouette 0.560), separating a multi-system cluster (4072 reports; 10.1%) enriched for neuropsychiatric, musculoskeletal and sensory terms (lifts: memory impairment 8.6, muscle atrophy 8.3, dry eye 7.8). Excluding seriousness and outcome left the cluster essentially unchanged (91.4% retained; κ 0.95), indicating definition by event topology, not case severity; independent algorithms recovered the same subgroup across granularities. Post hoc, the cluster was disproportionately disabling (43.0% vs. 11.7%). The fixed signature classified 14.9% of fluoroquinolone reports vs. 5.3% (macrolides) and 3.9% (amoxicillin).

Conclusions: Unsupervised clustering of FAERS data identified, without prior clinical input, a reproducible multi-system adverse-event pattern among fluoroquinolone reports, potentially supporting the feasibility of unsupervised exploratory pattern detection in pharmacovigilance. Given the limitations of spontaneous reporting databases, the findings are strictly hypothesis-generating.

药物警戒中用于多系统不良事件模式检测的无监督机器学习:FAERS中氟喹诺酮类报告的概念验证分析。
目的:传统的药物警戒检测单一药物事件关联,但不能轻易表征多系统不良事件模式,如氟喹诺酮类药物相关残疾。我们为此目的评估了无监督机器学习,以氟喹诺酮类药物为例。方法:我们分析了FDA不良事件报告系统(FAERS, 2004-2025)中40127例成人氟喹诺酮类药物的主要可疑报告。将事件编码为二进制MedDRA首选项(PT)和系统器官类矩阵;严重性和结果被排除在聚类之外,仅用于事后分析。首先采用k-means进行多重对应分析,并通过k-modes和分层聚类进行验证。聚类数(k = 2-15)采用具有自举稳定性的内部效度指标进行评价。比较药物为大环内酯类药物(n = 39948)和阿莫西林(n = 16310)。结果:在PT水平上,剪形和Calinski-Harabasz指数在两个聚类(Davies-Bouldin为三个,剪形为0.560)中最优,分离出一个多系统聚类(4072份报告,10.1%),丰富了神经精神病学,肌肉骨骼和感觉方面(提升:记忆障碍8.6,肌肉萎缩8.3,干眼7.8)。排除严重程度和结果后,聚类基本保持不变(91.4%保留;κ 0.95),表明由事件拓扑定义,而不是病例严重程度;独立的算法在不同的粒度上恢复相同的子群。事后,群集不成比例地致残(43.0%对11.7%)。固定签名分类14.9%的氟喹诺酮类报告,5.3%(大环内酯类)和3.9%(阿莫西林)。结论:FAERS数据的无监督聚类在没有事先临床输入的情况下,确定了氟喹诺酮类药物报告中可重复的多系统不良事件模式,潜在地支持了在药物警戒中无监督探索性模式检测的可行性。考虑到自发报告数据库的局限性,这些发现是严格的假设生成。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
6.30
自引率
8.80%
发文量
419
审稿时长
1 months
期刊介绍: Published on behalf of the British Pharmacological Society, the British Journal of Clinical Pharmacology features papers and reports on all aspects of drug action in humans: review articles, mini review articles, original papers, commentaries, editorials and letters. The Journal enjoys a wide readership, bridging the gap between the medical profession, clinical research and the pharmaceutical industry. It also publishes research on new methods, new drugs and new approaches to treatment. The Journal is recognised as one of the leading publications in its field. It is online only, publishes open access research through its OnlineOpen programme and is published monthly.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书